ES2486845T3 - Torio-227 para ser usado en radioterapia de enfermedad de partes blandas - Google Patents
Torio-227 para ser usado en radioterapia de enfermedad de partes blandas Download PDFInfo
- Publication number
- ES2486845T3 ES2486845T3 ES04727587.0T ES04727587T ES2486845T3 ES 2486845 T3 ES2486845 T3 ES 2486845T3 ES 04727587 T ES04727587 T ES 04727587T ES 2486845 T3 ES2486845 T3 ES 2486845T3
- Authority
- ES
- Spain
- Prior art keywords
- thorium
- addressing
- effective amount
- tissue disease
- soft tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 title abstract 5
- 208000016247 Soft tissue disease Diseases 0.000 title abstract 2
- 238000001959 radiotherapy Methods 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 231100001180 nonmyelotoxic Toxicity 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308731.9A GB0308731D0 (en) | 2003-04-15 | 2003-04-15 | Method of radiotherapy |
| GB0308731 | 2003-04-15 | ||
| PCT/GB2004/001654 WO2004091668A1 (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2486845T3 true ES2486845T3 (es) | 2014-08-19 |
Family
ID=35385222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04727587.0T Expired - Lifetime ES2486845T3 (es) | 2003-04-15 | 2004-04-15 | Torio-227 para ser usado en radioterapia de enfermedad de partes blandas |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1617876B1 (https=) |
| JP (2) | JP5006032B2 (https=) |
| KR (2) | KR101274867B1 (https=) |
| CN (1) | CN100586484C (https=) |
| AU (1) | AU2004229218B2 (https=) |
| BR (1) | BRPI0409387B8 (https=) |
| CA (1) | CA2522148C (https=) |
| CY (1) | CY1115407T1 (https=) |
| DK (1) | DK1617876T3 (https=) |
| EA (1) | EA008195B1 (https=) |
| ES (1) | ES2486845T3 (https=) |
| IL (1) | IL171148A (https=) |
| MX (1) | MXPA05010804A (https=) |
| NO (1) | NO332931B1 (https=) |
| NZ (3) | NZ595758A (https=) |
| PL (1) | PL1617876T3 (https=) |
| PT (1) | PT1617876E (https=) |
| ZA (1) | ZA200507983B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ595758A (en) * | 2003-04-15 | 2013-02-22 | Algeta As | Thorium-227 for use in radiotherapy of soft tissue disease |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| GB201600153D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| EP3554257B1 (en) | 2016-12-15 | 2023-07-12 | Société des Produits Nestlé S.A. | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
| FR3088769B1 (fr) * | 2018-11-15 | 2020-12-25 | Orano Med | Procede de preparation d'au moins un generateur a haute teneur en radium-228 |
| RU2767567C1 (ru) * | 2020-10-27 | 2022-03-17 | Станислав Анатольевич Дороватовский | Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата |
| CN119912489B (zh) * | 2024-12-23 | 2026-02-03 | 中国科学院近代物理研究所 | 一种膦酸钍框架材料及其制备方法和在钍镭发生器中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU629367B2 (en) * | 1989-06-19 | 1992-10-01 | Akzo N.V. | Radioimmunotherapy using alpha-particles emission |
| JPH07505886A (ja) * | 1992-04-13 | 1995-06-29 | ザ ダウ ケミカル カンパニー | マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体 |
| CN1073860C (zh) * | 1998-08-20 | 2001-10-31 | 中国核动力研究设计院 | 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法 |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| AU4906901A (en) * | 2000-02-25 | 2001-09-17 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| ITMI20022411A1 (it) | 2002-11-14 | 2004-05-15 | Bracco Imaging Spa | Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate. |
| NZ595758A (en) * | 2003-04-15 | 2013-02-22 | Algeta As | Thorium-227 for use in radiotherapy of soft tissue disease |
-
2004
- 2004-04-15 NZ NZ595758A patent/NZ595758A/xx not_active IP Right Cessation
- 2004-04-15 PT PT47275870T patent/PT1617876E/pt unknown
- 2004-04-15 DK DK04727587.0T patent/DK1617876T3/da active
- 2004-04-15 ES ES04727587.0T patent/ES2486845T3/es not_active Expired - Lifetime
- 2004-04-15 JP JP2006506137A patent/JP5006032B2/ja not_active Expired - Lifetime
- 2004-04-15 KR KR1020117003862A patent/KR101274867B1/ko not_active Expired - Lifetime
- 2004-04-15 NZ NZ543044A patent/NZ543044A/en not_active IP Right Cessation
- 2004-04-15 KR KR1020057019497A patent/KR20060015507A/ko not_active Ceased
- 2004-04-15 EP EP04727587.0A patent/EP1617876B1/en not_active Expired - Lifetime
- 2004-04-15 PL PL04727587T patent/PL1617876T3/pl unknown
- 2004-04-15 MX MXPA05010804A patent/MXPA05010804A/es active IP Right Grant
- 2004-04-15 CA CA2522148A patent/CA2522148C/en not_active Expired - Lifetime
- 2004-04-15 NZ NZ606996A patent/NZ606996A/en not_active IP Right Cessation
- 2004-04-15 CN CN200480016329A patent/CN100586484C/zh not_active Expired - Lifetime
- 2004-04-15 BR BRPI0409387A patent/BRPI0409387B8/pt not_active IP Right Cessation
- 2004-04-15 ZA ZA200507983A patent/ZA200507983B/en unknown
- 2004-04-15 AU AU2004229218A patent/AU2004229218B2/en not_active Expired
- 2004-04-15 EA EA200501456A patent/EA008195B1/ru not_active IP Right Cessation
-
2005
- 2005-09-28 IL IL171148A patent/IL171148A/en active IP Right Grant
- 2005-11-15 NO NO20055390A patent/NO332931B1/no unknown
-
2011
- 2011-12-02 JP JP2011265169A patent/JP5468597B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-28 CY CY20141100569T patent/CY1115407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Effect of shock wave therapy on acute fractures of the tibia: a study in a dog model. | |
| Martini et al. | Effect of extracorporeal shock wave therapy on osteoblastlike cells | |
| Ueno et al. | A clinicopathologic study of ameloblastoma | |
| ES2486845T3 (es) | Torio-227 para ser usado en radioterapia de enfermedad de partes blandas | |
| Franzén et al. | Oral implant rehabilitation of patients with oral malignancies treated with radiotherapy and surgery without adjunctive hyperbaric oxygen. | |
| Brusamolino et al. | Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity | |
| Mark et al. | Fibrosarcoma of the head and neck: the UCLA experience | |
| ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
| Silverberg et al. | Osteoclastoma‐like giant cell tumor of the thyroid. Report of a case with prolonged survival following partial excision and radiotherapy | |
| ATE454166T1 (de) | Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern | |
| ES2080837T3 (es) | Tratamiento de estados y enfermedades. | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| BR0010648A (pt) | Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril | |
| EA200401522A1 (ru) | Противотуберкулёзный препарат: композиции и способы | |
| COLEMAN | Chemotherapy for large-cell lymphoma: optimism and caution | |
| ES2136673T3 (es) | Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos. | |
| Frankenthaler et al. | Fibrosarcoma of the head and neck | |
| BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
| Oh et al. | Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases | |
| DeVita Jr | A selective history of the therapy of Hodgkin's disease. | |
| BR112022026094A2 (pt) | Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit | |
| Wallenborn et al. | Radiation recall supraglottitis: a hazard in head and neck chemotherapy | |
| MAEDA et al. | High-energy, low-dose radiation therapy for aneurysmal bone cyst: report of a case | |
| Schultz et al. | Management of presumptive or proven Hodgkin's disease of the liver: A new radiotherapy technique | |
| ES2089286T3 (es) | Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos. |